-
Pfanstiehl Launches New cGMP-produced, Parenteral Grade Histidine and Histidine HCl For Biopharmaceutical Formulations
Following a record 100th year in business, Pfanstiehl has launched high purity, low endotoxin, low metal L-Histidine and L-Histidine Hydrochloride Monohydrate and established a new quality standard for amino acids. Amino acids are critical components utilized in bioprocessing for both upstream and downstream applications. With the ever-increasing regulatory requirements placed on bioprocessing components, there is […]
-
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Sodium Succinate (Hexahydrate) for Biopharmaceutical and Pharmaceutical Formulations
Pfanstiehl has announced the launch of the first cGMP Sodium Succinate Hexahydrate (NF) to the market, which is compliant with the new USP Monograph established in 2017. Pfanstiehl previously launched the first cGMP Sodium Succinate Anhydrous (NF) to the market in March 2018. This is the only available cGMP grade Sodium Succinate Hexahydrate (#D-161) product available on the market. […]
-
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Arginine For Biopharmaceutical and Pharmaceutical Formulations
As Pfanstiehl approaches its 100th anniversary in 2019, the company has launched a new high purity, low endotoxin, and low metal L-Arginine (USP, EP, JP, ChP), manufactured in the United States under strict cGMP, ICH Q7 compliant conditions. This is the first amino acid Pfanstiehl has launched and they have others in development. Amino acids have been […]
-
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Sodium Succinate (Anhydrous) for Biopharmaceutical and Pharmaceutical Formulations
Pfanstiehl has announced the launch of the first cGMP Sodium Succinate Anhydrous (NF) to the market, which is compliant with the new USP Monograph established in 2017. This is the only available cGMP grade Sodium Succinate product available on the market. It is highly pure, has low endotoxin and is manufactured in the US under strict ICH Q7 compliant […]
-
Pfanstiehl Launches a new cGMP-produced, Parenteral Grade Mannitol For Biopharmaceutical and Pharmaceutical Formulations
Pfanstiehl has announced the launch of a new high purity, low endotoxin, and low metal Mannitol (USP, EP, JP, ChP), manufactured in the US under strict cGMP, ICH Q7 compliant conditions. Mannitol is a tried and true platform excipient used in a wide range of therapeutic formulations. Mannitol has demonstrated its utility as a stand-alone […]
-
Pfanstiehl Launched a new cGMP-produced Galactose for Cell Culture Media Optimization & Production of Therapeutic Recombinant Glycoproteins
As part of Pfanstiehl’s continual commitment to producing the industry’s highest purity, lowest endotoxin and lowest metals for bioprocessing components, two new D-Galactose products have been launched. Pfanstiehl’s new D-Galactose (Plant Derived) High Purity / Low Endotoxin – Low Metal, EP (G-126-3) product and D-Galactose (Plant Derived) High Purity / Low Endotoxin (G-126-2) product are […]
-
Pfanstiehl Establishes Asian Subsidary
Pfanstiehl, a leading US-based manufacturer of cGMP high purity, low endotoxin injectable grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications, has announced the establishment of its Asian subsidiary, Pfanstiehl Singapore Pte. Ltd. The subsidiary will be anchored in Singapore, but will provide the foundation to support Pfanstiehl’s growing customer base throughout the […]
-
Pfanstiehl Establishes European Subsidary.
Pfanstiehl, a leading US-based manufacturer of cGMP high purity, low endotoxin injectable grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications, has announced the establishment of its European subsidiary, Pfanstiehl GmbH. The subsidiary will be anchored in Switzerland, but will provide the foundation to support Pfanstiehl’s growing customer base throughout Europe, the Middle […]
